Bogliolo, M.,
Catucci, I.,
Caleca, L.,
Lasheras, S.V.,
Pujol, R.,
Kiiski, J.I.,
Muranen, T.A.,
Barnes, D.R.,
Dennis, J.,
Michailidou, K.,
Bolla, M.K.,
Leslie, G.,
Figlioli, G. (2019) , with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We
tested the three
Gurevich, KG,
Urakov, AL,
Rozit, GA,
Klen, EE,
Samorodov, AV,
Khaliullin, FA (2021) , which showed the absence of predicted toxic risks and were superior to the reference
drugSultanova, .R.M,
Khusnutdinova, N.S.,
Borisova, Yu. G.,
Raskildina, G.Z.,
Meshcheryakova, S.A.,
Zlotsky, S.S.,
Valiullina, Z.A.,
Karamova, E.V.,
Samorodov, A.V. (2024) The main goal of applying antiplatelet
drugs is a reduced probability of thrombosis so that active
intraperitoneally daily from Day 0 to Day +6; 3ETD (2 mg/kg) and the reference
drug amitriptyline (10 mg/kg) were
Meshcheryakova, S.,
Shumadalova, A.,
Beylerli, O.,
Gareev, I.,
Zhao, S.,
Wu, J. (2022) of the bacterial chromosome. 12 new uracil S-derivatives were obtained and
tested for their in vitro antimicrobial